Floatz logo

Therapeutic Asset Ratings

166 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Abbv-916
Alzheimer's Disease (AD)
AbbVieP2B (57)
Abbv-932
Bipolar I Disorder
AbbVieP2B (57)
Abbv-932
Bipolar II Disorder
AbbVieP2B (57)
Abbv-706
Small Cell Lung Cancer
AbbVieP3B (56)
Telisotuzumab Adizutecan
Metastatic Colorectal Cancer
AbbVieP3B (56)
Imgn632
Acute Myeloid Leukemia
AbbVieP2/3B (56)
Telisotuzumab Adizutecan
Non-Small Cell Lung Cancer
AbbVieP2/3B (56)
Budigalimab
Hepatocellular Carcinoma
AbbVieP2/3CCC (54)
LENVATINIB
Squamous Cell Non Small Cell Lung Cancer
AbbVieP1/2CCC (54)
Abbv-119
Cystic Fibrosis (CF)
AbbVieP2CCC (53)
Abbv-400
Unresectable Metastatic Colorectal Cancer
AbbVieP2CCC (53)
Abbv-576
Cystic Fibrosis (CF)
AbbVieP2CCC (53)
Amelenodor
Ulcerative Colitis
AbbVieP2CCC (53)
Brimonidine
Folate Receptor-Alpha Positive
AbbVieP2CCC (53)
Brimonidine
Recurrent Ovarian Cancer
AbbVieP2CCC (53)
Carboplatin
Neoadjuvant
AbbVieP2CCC (53)
Icalcaprant
Bipolar I Disorder
AbbVieP2CCC (53)
Icalcaprant
Bipolar II Disorder
AbbVieP2CCC (53)
Imgn151
Gynecologic Cancers
AbbVieP2CCC (53)
Imgn151
Platinum-Sensitive Ovarian Cancer
AbbVieP2CCC (53)
Irinotecan
Neoadjuvant
AbbVieP2CCC (53)
METHYLPREDNISOLONE ACETATE IMPURITY E
Folate Receptor-Alpha Positive
AbbVieP2CCC (53)
METHYLPREDNISOLONE ACETATE IMPURITY E
Recurrent Ovarian Cancer
AbbVieP2CCC (53)
Mirvetuximab Soravtansine
Folate Receptor-Alpha Positive
AbbVieP2CCC (53)
Mirvetuximab Soravtansine
Neoadjuvant
AbbVieP2CCC (53)
Showing 26 to 50 of 166 assets
PreviousPage 2 of 7Next